Coherus Oncology Inc (CHRS)

SG&A Expense Growth

-9.31%

Quarterly · Period ending:

CHRS logo

CHRS SG&A Expense Growth

Latest reported-9.31%
CHRS Quarterly SG&A Growth (QoQ) (0.00% → -9.31%)
High-resolution chart · PNG

CHRS sg&a expense growth history

Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.

Coherus Oncology Inc SG&A Expense Growth — Quarterly
Period endingSG&A Expense Growth
-9.3057%
-2.139%
3.4076%
-12.32%
0.0538%
-36.9809%
18.8608%
-1.1972%
-12.5945%
-18.7134%
2.6335%
6.8226%
-8.1562%
-8.3326%
19.607%
-12.5692%
5.1751%
-2.5953%
25.3651%
-1.041%
2.4219%
4.5048%
17.8495%
-6.0731%
-3.6719%
-1.9961%
13.3279%
-12.6948%
11.5442%
-3.419%
33.3911%
37.9425%
10.9429%
10.6757%
7.0698%
-40.5558%
25.1556%
22.9436%
12.085%
21.1812%
-1.2107%
3.8826%
7.9284%
15.3%
44.7546%
-1.5357%
55.4662%
0.0251%
16.2818%
37.0044%
6.0297%
77.8701%
2.7153%
0%
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.